Global private equity and venture capital news and research

Posts Tagged ‘SV Life Sciences’

16 April 2014

Biopharma developer PanOptica scores $45m Series B investment

Biopharmaceutical company PanOptica has raised up to $45m in a Series B financing, co-led by new participant Novo Ventures and existing investor Third Rock Ventures, alongside founding investor SV Life Sciences.

1 April 2014

Investors exit biopharma services company Aptiv in $144m sale

Investors including the Halifax Group, SV Life Sciences and Comvest Partners have exited their stake in biopharmaceutical and medical device development services company Aptiv Solutions to ICON for $143.5m.

25 February 2014

Novo Ventures leads $49m Series B for anti-acne business Thesan Pharmaceuticals

skin5_lrg Biotechnology business Thesan Pharmaceuticals, which aims to treat skin disorders including acne and dermatitis, has picked up $49m of Series B financing led by existing backer Novo Ventures.

8 July 2013

OncoEthix raises $19m in SV Life Sciences-led Series B

Venture capital firm SV Life Sciences has led a CHF18m ($19m) Series B round for Swiss oncology drug development company OncoEthix.

28 February 2013

Panorama Capital backs CardioKinetix’s $48m Series E round

news_heartmonitor.lrg Medical devices maker CardioKinetix has successfully raised $48m via a Series E funding round, which was backed by new investor Panorama Capital.

7 January 2013

VC firm SV Life Sciences upgrades management team

International life sciences venture capital firm SV Life Sciences has appointed Darren Black as managing partner and Tom Flynn as partner.

10 December 2012

Astellas joins existing venture investors in £3.75m Bicycle Therapeutics deal

bicycle_sq Astellas Venture Management, the venture arm of Astellas Pharma, has backed a £3.75m financing round for UK business Bicycle Therapeutics.

17 October 2012

SV Life Sciences, Third Rock Ventures launch Cibiem with $10m Series A

nerves_lrg SV Life Sciences and Third Rock Ventures have led a $10m Series A financing to launch nervous system-related disease treatment provider Cibiem.

7 September 2012

UK pharma start-up Karus Therapeutics closes Series B

UK pharmaceutical company Karus Therapeutics has closed its Series B round, with investors including SV Life Sciences, New Leaf Ventures and a number of angels.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014